1
New Contraindications to Coadministration of Atazanavir
Medscape Infectious Diseases, 26.04.2024
Tilføjet 26.04.2024
New restrictions have been imposed by the European Medicines Agency on the coadministration of the anti-HIV drug atazanavir with a variety of other agents. Medscape Medical News
Læs mere
2
MASLD Plus HIV Ups Risk for CVD But Not Liver Disease
Medscape Infectious Diseases, 26.04.2024
Tilføjet 26.04.2024
A large study reveals an increased risk for adverse cardiovascular events but not for liver disease progression in adults with MASLD disease and HIV infection. Medscape Medical News
Læs mere
3
Investigation of Presumptive HIV Transmission Associated with Receipt of Platelet-Rich Plasma Microneedling Facials at a Spa Among Former Spa Clients - New Mexico, 2018-2023
Morbidity and Mortality Weekly Report (MMWR), 26.04.2024
Tilføjet 26.04.2024
This report describes an investigation of multiple HIV infections among people who received microneedling facials.
Læs mere
4
Questioning risk compensation: pre-exposure prophylaxis (PrEP) and sexually transmitted infections among men who have sex with men, capital region of Denmark, 2019 to 2022
Sebastian von Schreeb, Susanne Kriegel Pedersen, Hanne Christensen, Kristina Melbardis Jørgsensen, Lene Holm Harritshøj, Frederik Boetius Hertz, Magnus Glindvad Ahlström, Anne-Mette Lebech, Suzanne Lunding, Lars Nørregaard Nielsen, Jan Gerstoft, Gitte Kronborg and Frederik N Engsig
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundPre-exposure prophylaxis (PrEP) effectively prevents HIV, but its association with sexually transmitted infections (STIs) has raised concerns about risk compensation, potentially impacting the expansion of PrEP programmes. AimWe examined the relationship between PrEP and the incidence of chlamydia, gonorrhoea and syphilis. MethodsIn this prospective cohort study, we compared STI rates before and after PrEP initiation among users in the capital region of Denmark (2019–2022), calculating incidence rate ratios adjusted for age and testing frequency (aIRR). To pinpoint when increases began, we plotted weekly STI rates, adjusting the timeline to correspond with PrEP initiation. ResultsThe study included 1,326 PrEP users with a median age of 35 years. The STI incidence rate per 100,000 person-years rose from 35.3 before to 81.2 after PrEP start, with an aIRR of 1.35 (95% CI: 1.18–1.56). Notably, this increase preceded PrEP initiation by 10–20 weeks. Specific aIRR for chlamydia, gonorrhoea and syphilis were 1.23 (95% CI: 1.03–1.48), 1.24 (95% CI: 1.04–1.47) and 1.15 (95% CI: 0.76–1.72), respectively. In subanalyses for anatomical sites aIRR was 1.26 (95% CI: 1.01–1.56) for rectal chlamydia and 0.66 (95% CI: 0.45–0.96) for genital gonorrhoea. ConclusionWe found a 35% increase in STI incidence associated with PrEP use. It started before PrEP initiation, challenging the assumption that PrEP leads to risk compensation. Instead, the data suggest that individuals seek PrEP during periods of heightened sexual risk-taking. Consequently, PrEP programmes should include sexual health consultations, STI testing, treatment and prevention strategies to prevent HIV and improve sexual health.
Læs mere
5
Tuberculosis Preventive Treatment Update - U.S. President's Emergency Plan for AIDS Relief, 36 Countries, 2016-2023
Morbidity and Mortality Weekly Report (MMWR), 21.03.2024
Tilføjet 21.03.2024
This report describes trends in the initiation and completion of preventive treatment for tuberculosis in people with HIV through PEPFAR-supported programs.
Læs mere